regulatory
confidence high
sentiment positive
materiality 0.70
GRI Bio receives FDA Orphan Drug Designation for GRI-0621 in IPF
GRI Bio, Inc.
- FDA granted Orphan Drug Designation to GRI-0621 for idiopathic pulmonary fibrosis.
- Designation provides potential 7-year U.S. market exclusivity upon approval.
- GRI-0621 is an oral RARβ/γ selective agonist that met endpoints in Phase 2a trial (35 patients).
- IPF affects fewer than 200,000 U.S. patients; significant unmet medical need exists.